TIBBI ONKOLOJI - GERIATRIK ONKOLOJI, ss.54-61, 2020 (SCI-Expanded)
Although there have been many new developments in the systemic treament of cancer such as thyrosin kinase inhibitors and immunoterapy in the recent years, chemotherapy is still the main treatment modality. However aging related processes may reduce to chemotherapy tolerance and increasechemotoxicity in elderly patients. Aging is a heterogeneous process and personalization of cancer treatment is necessary in geriatric patients. In the general population, Performace Status (PS) has been used to estimate tolerance to chemotherapy, but in the elderly population it is not useful. In this review, chemotoxicity prediction models that will help in making daily chemotherapy decision and predict tolerance to chemotherapy will be scrutinized.